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Purpose/Objective: Our clinic is a long-term user of a 1st 
generation trans-abdominal (TA) ultrasound image guidance 
(USIG) system (BAT, Best Nomos Inc) for prostate cancer 
treatments. We are also an early adopter and development 
partner for a new, second generation 3D USIG system 
(Clarity, Elekta Inc), which allows for trans-perineal (TP) 
localization and intra-fractional tracking of the prostate. This 
new system has been evaluated at our institution, by direct 
comparison with the previously established TA method for 
prostate alignment.  
Materials and Methods: Patients were positioned according 
to routine clinical protocol and aligned to skin marks using 
treatment room lasers. TP USIG was performed and TP shifts 
from tattoo were performed and recorded prior to 
performing TA USIG for verification purposes only. The 
observed differences of TA USIG from TP shifts were 
recorded. A total of 569 fractions delivered to 30 prostate 
cancer patients were thus analyzed for agreement between 
the two USIG systems. For each patient, a graph and tables 
showing shift of skin marks to TP USIG and agreement 
between the USIG systems of all applicable fractions were 
generated.  
Results: The mean TP-based initial shift from tattoo was -
1.78, -0.27, and -2.36 mm in left-right (LR), anterior-
posterior (AP), and superior-inferior (SI) directions, 
respectively. The average difference (AD) between the two 
USIG systems was -0.06, -0.05, and -0.02 mm in LR, AP and SI 
directions respectively. The respective standard deviations of 
the AD were 0.19, 0.45 and 0.38 mm. Image 1 shows a sample 
of patients, with the dot representing the mean agreement 
between the USIG systems for a patient. The error bars 
represent the patient specific standard deviation.  
 
 
Image 1: Agreement of prostate localization for two US IG 
systems. 
  
Conclusions: Data evaluated here, which includes the initial 
competency development period for the new TPUS 
acquisition approach in our clinic, showed the average 
difference between TPUS and TAUS, across all 569 fractions 
evaluated here as less than 1 mm in the three principle 
directions (LR, AP, SI). There was no systematic difference 
found between the two systems. In addition to superior 
image quality, a prime observed advantage of the TP USIG 
approach was the intra-fraction tracking capability. 
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Purpose/Objective: It has been demonstrated that non-
adherence to protocol-specified radiotherapy (RT) 
requirements is associated with reduced survival, local 
control and potentially increased toxicity [1]. Thus, quality 
assurance (QA) of RT is important when evaluating the results 
of clinical trials. RT-QA of large multicentre-trials, however, 
requires substantial effort and resources. Recently, we 
presented a digital QA platform, the CIRRO dose plan bank, 
which allows for central review of such trials. Here, we 
present our RT-QA results from the latest completed clinical 
protocol from the Danish Head and Neck Cancer Group 
(DAHANCA). 
Materials and Methods: The clinical results of the DAHANCA 
19 randomized phase III trial evaluated the effect of 
concurrent EGFR-inhibition during primary curative (chemo) 
radiotherapy in patients with head and neck squamous cell 
carcinoma (HNSCC). A total of 504 Danish patients entered 
the protocol in 2007-2012. Patients received RT at 5 different 
oncology centers to a total dose of 66-68Gy, 2Gy/fx, 6 
fx/week. For the current QA analysis, total treatment time, 
CTV coverage, and near-max doses to the spinal cord and 
brainstem including the corresponding planning risk volumes 
(PRVs) were evaluated according to 2004 DAHANCA 
guidelines. Each QA parameter was scored within three 
categories: 1) Full compliance to protocol guidelines, 2) 
Minor deviations: Not according to guidelines, but without 
clinical relevance, and 3) Major deviations: Clinical 
significant deviation. Categories 1) and 2) are clinical 
acceptable, whereas category 3) is clinical unacceptable. 
Results: The complete digital RT dataset was uploaded for all 
504 patients and QA parameters were extracted. The results 
are shown in table 1. Not all patients contribute to the PRV 
data, since the PRV concept was introduced in the Danish 
clinics shortly after 2007. Furthermore, 13 patients (2.6%) 
were eliminated from the CTV QA due to challenges to 
extract dose summations (e.g. re-scans and primary/ boost 
dose plans) from the database. A total of 11 major deviations 
were recorded. Four major deviations in CTV1 dose coverage 
were due to clinical considerations of the tolerance dose to 
the spinal cord, thus compromising target dose. Five of the 
major deviations in total treatment time were related to co-
morbidities, such as alcohol- or cardiac related matters and 
hospitalization. The remaining two cases were due to 
tracheotomy procedures and subsequent re-scans, which 
delayed the RT course. 
 
 
Table 1: Summary of results from RT-QA of the DAHANCA 
protocol. 
 
Conclusions: RT dose plans in DAHANCA 19 adhere well to 
national clinical guidelines. A total of 11 major deviations 
were found in 504 patients. All majors were clinically well 
accounted for. 
[1] D. C. Weber et al.: 'QA makes a clinical trial stronger: 
Evidence-based medicine in radiation therapy', Radiother. 
Oncol. 105 (2012) 4-8. 
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Purpose/Objective: During lung cancer radiotherapy, 
anatomical changes are frequently observed on cone-beam 
CT scans used for position verification and adaptive 
replanning might be needed without prolongation of overall 
treatment time. A method for fast re-evaluation of the dose 
distribution on small FOV CBCTs was developed. The 
influence of anatomical changes on the dose distribution was 
evaluated in a group of lung cancer patients. 
Materials and Methods: In 13 lung cancer cases a CBCT 
(Elekta XVI) and a repeat planning CT (Philips Brilliance) were 
obtained on the same day to ensure identical anatomy. The 
CBCT was registered on the repeat CT, which in turn was 
registered to the original planning CT according to the 
clinically applied patient shift. The original treatment plan 
and delineated structures were transferred to the repeat CT 
and CBCT to recalculate the dose. Dose calculation on the 
CBCT was done in Pinnacle3 v9.6 (Philips) by (1) adding the 
remainder of the body contour missing on the CBCT by taking 
the body contour of the planning CT with a density override 
equal to one; (2) Overriding the density of the CBCT outside 
the patient to 0; (3) Deriving a patient-specific HU-to-density 
table by comparing CT values of corresponding points on the 
CBCT and original planning CT; (4) Recalculating the dose 
using the individualised HU-to-density table and a standard 
table for XVI lung scans. Clinically relevant dose parameters 
were compared to assess the accuracy of this approach. The 
impact of anatomical changes on the dose distribution was 
evaluated. 
Results: In all clinical cases the CBCT could be successfully 
registered on the repeat CT, and only minor differences in 
the anatomy were visible. A complete dose evaluation could 
be performed in ~ 10 minutes. GTV and PTV coverage, the 
dose to the lungs (V20Gy, MLD), oesophagus (mean dose, V35Gy), 
spinal cord (max dose) and heart (mean dose) were scored 
for the repeat CT and CBCT dose calculation. Figure 1 
displays the average and standard deviation (error bars) of 
the absolute relative difference of the dose metrics between 
repeat CT and CBCT, both using a standard HU-to-density 
table for the CBCT lung XVI protocol, as well as a patient-
specific table. A good agreement between the dose 
distributions recalculated on CBCT and repeat CT was 
observed for most patients when a patient-specific HU-to-
density table was used.  
Compared to the planning CT, the observed dose differences 
did not necessitate plan adaptation in 10 of the 13 cases, as 
the target coverage was sufficient and tolerance levels of the 
OARs were not exceeded. Three cases with tumour shifts 
leading to an insufficient coverage of the target were 
replanned. 
